A randomized, double-blind, placebo-controlled, parallel-arm Phase III trial of tesofensine in patients with obesity

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-arm Phase III trial of tesofensine in patients with obesity

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Tesofensine (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Sponsors NeuroSearch
  • Most Recent Events

    • 12 Apr 2017 According to a Saniona media release, this trial is expected to be completed within two years from initiation.
    • 12 Apr 2017 Status changed from planning to not yet recruiting, according to a Saniona media release.
    • 12 Apr 2017 According to a Saniona media release, the Mexican regulatory authority, Cofepris, has approved this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top